Recent progress in pancreatic cancer

CA Cancer Journal for Clinicians

Volumn 63, Issue 5, 2013, Pages 318-348

  Wolfgang, Christopher L ^a   Herman, Joseph M ^a   Laheru, Daniel A ^a   Klein, Alison P ^a,b   Erdek, Michael A ^a   Fishman, Elliot K ^a   Hruban, Ralph H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

medical oncology; molecular biology; pancreatic neoplasms; radiation oncology; radiology

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GEMFIBROZIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; NARCOTIC ANALGESIC AGENT; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; BLOOD TOXICITY; BRCA2 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CDKN2A GENE; CLINICAL FEATURE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; GENE; HAND FOOT SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; KRAS GENE; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PALB2 GENE; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PANCREATITIS; PATIENT CARE; PATIENT SELECTION; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; REVIEW; SEDATION; SIDE EFFECT; STOMATITIS; TERMINAL CARE; TUMOR SUPPRESSOR GENE;

MEDICAL ONCOLOGY; MOLECULAR BIOLOGY; PANCREATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOLOGY;

ADENOCARCINOMA; HUMANS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 84883670305     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21190     Document Type: Review

References (239)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012; 23: 1880-1888.
3. Maisonneuve P, Lowenfels AB,. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010; 28: 645-656.
4. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009; 69: 3681-3688.
5. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M,. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92: 2076-2083.
6. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM,. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005; 129: 504-511.
7. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Pancreatic Cancer Cohort Consortium (PanScan). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010; 170: 791-802.
8. Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012; 23: 374-382.
9. Duell EJ, Lucenteforte E, Olson SH, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012; 23: 2964-2970.
10. Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer. 2010; 127: 1421-1428.
11. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C,. Reported family aggregation of pancreatic cancer within a population- based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol. 1991; 10: 183-196.
12. Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF,. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol. 1988; 128: 324-336.
13. Price TF, Payne RL, Oberleitner MG,. Familial pancreatic cancer in south Louisiana. Cancer Nurs. 1996; 19: 275-282.
14. Schenk M, Schwartz AG, O'Neal E, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst. 2001; 93: 640-644.
15. Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010; 102: 119-126.
16. Wang L, Brune KA, Visvanathan K, et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2829-2834.
17. Shi C, Hruban RH, Klein AP,. Familial pancreatic cancer. Arch Pathol Lab Med. 2009; 133: 365-374.
18. Canto MI, Hruban RH, Fishman EK, et al. American Cancer of the Pancreas Screening (CAPS) Consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012; 142: 796-804.
19. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013; 62: 339-347.
20. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011; 19: 472-478.
21. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res. 2005; 11: 7508-7515.
22. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996; 56: 5360-5364.
23. Ozcelik H, Schmocker B, DiNicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genet. 1997; 16: 17-18.
24. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009; 27: 433-438.
25. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 342-346.
26. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002; 62: 3789-3793.
27. Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011; 16: 1397-1402.
28. Tischkowitz MD, Sabbaghian N, Hamel N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009; 137: 1183-1186.
29. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010; 78: 490-494.
30. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324: 217.
31. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011; 10: 3-8.
32. Thompson D, Easton DF,. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94: 1358-1365.
33. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009; 8: 1-5.
34. Moskaluk CA, Hruban RH, Lietman AS, et al. Novel germline p16 (INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online. Hum Mutat. 1998; 12: 70-73.
35. Rutter JL, Bromley CM, Goldstein AM, et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer. 2004; 101: 2809-2816.
36. Vasen HF, Gruis NA, Frants RR, van Der Velden, Hille ET, Bergman W,. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000; 87: 809-811.
37. Santillan AA, Cherpelis BS, Glass LF, Sondak VK,. Management of familial melanoma and nonmelanoma skin cancer syndromes. Surg Oncol Clin N Am. 2009; 18: 73-98.
38. Rustgi AK,. The genetics of hereditary colon cancer. Genes Dev. 2007; 21: 2525-2538.
39. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009; 302: 1790-1795.
40. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR,. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001; 158: 527-535.
41. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 2000; 156: 1641-1651.
42. Nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002; 8: 2536-2540.
43. Solomon S, Whitcomb DC,. Genetics of pancreatitis: an update for clinicians and genetic counselors. Curr Gastroenterol Rep. 2012; 14: 112-117.
44. Whitcomb DC,. Genetics of alcoholic and nonalchoholic pancreatitis. Curr Open Gastroenterol. 2012; 28: 501-506.
45. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996; 14: 141-145.
46. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000; 25: 213-216.
47. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997; 89: 442-446.
48. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP,. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001; 286: 169-170.
49. Korsse SE, Harinck F, van Lier MG, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet. 2013; 50: 59-64.
50. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers Syndrome. Gastroenterology. 2000; 119: 1447-1453.
51. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4: 766-781.
52. Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 2001; 159: 2017-2022.
53. Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009; 101: 424-431.
54. Hruban RH, Pitman MB, Klimstra DS,. Tumors of the pancreas. In: AFIP Atlas of Tumor Pathology. Fourth Series, Fascicle 6. Washington, DC: American Registry of Pathology/Armed Forces Institute of Pathology; 2007.
55. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR,. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21: 418-429.
56. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62: 112-120.
57. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324: 1457-1461.
58. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007; 25: 319-325.
59. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29: 4548-4554.
60. Voong KR, Davison J, Pawlik TM, et al. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol. 2010; 41: 113-122.
61. Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS,. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J Surg Res. 2012; 174: 12-19.
62. Seidel G, Zahurak M, Iacobuzio-Donahue C, et al. Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol. 2002; 26: 56-63.
63. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010; 251: 470-476.
64. Hruban RH, Takaori K, Canto M, et al. Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg. 2007; 14: 255-263.
65. Maitra A, Fukushima N, Takaori K, Hruban RH,. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005; 12: 81-91.
66. Sipos B, Frank S, Gress T, Hahn S, Klöppel G,. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology. 2009; 9: 45-54.
67. Kanda M, Sadakari Y, Borges M, et al. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2012; doi: 10.1016/j.cgh.2012.11.016.
68. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 2012; doi: 10.1136/gutjnl-2012-302823.
69. Detlefsen S, Sipos B, Feyerabend B, Klöppel G,. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch. 2005; 447: 800-805.
70. Brune KA, Abe T, Canto MI, et al. Multifocal neoplastic precusor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006; 30: 1067-1076.
71. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC; 2010.
72. Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, García- Carbonero R, Carrato A,. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2011; 30 (suppl 1): 19-26.
73. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine Tumors. N Engl J Med. 2011; 364: 514-523.
74. Laffan TA, Horton KM, Klein AP, Fishman EK, Johnson PT, Hruban RH,. Prevelance of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008; 191: 802-807.
75. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013; 216:657-665.
76. Reddy S, Cameron JL, Scudiere J, et al. Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. J Am Coll Surg. 2009; 208: 950-957.
77. Wargo JA, Fernandez-del-Castillo C, Warshaw AL,. Management of pancreatic serous cystadenomas. Adv Surg. 2009; 43: 23-34.
78. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331: 1199-1203.
79. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806.
80. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011; 108: 21188-21193.
81. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Science Transl Med. 2011; 3: 92ra66.
82. Hruban RH, van Mansfeld ADM, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993; 143: 545-554.
83. Shi C, Fukushima N, Abe T, et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther. 2008; 7: 353-360.
84. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996; 271: 350-353.
85. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27: 1806-1813.
86. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009; 15: 4674-4679.
87. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012; 2: 41-46.
88. Williamson CT, Kubota E, Hamill JD, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med. 2012; 4: 515-527.
89. Omura N, Li CP, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 2008; 7: 1146-1156.
90. Missiaglia E, Donadelli M, Palmieri M, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR,. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene. 2005; 24: 199-211.
91. Fukushima N, Walter KM, Uek T, et al. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther. 2003; 2: 78-83.
92. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009; 6: e1000046.
93. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7: 3862-3868.
94. Hassan R, Bera T, Pastan I,. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10: 3937-3942.
95. Wang Q, Chaerkady R, Wu J, et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A. 2011; 108: 2444-2449.
96. Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009; 8: 340-346.
97. Matthaei H, Wylie D, Lloyd MB, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012; 18: 4713-4724.
98. Wan C, Shen Y, Yang T, Wang T, Chen L, Wen F,. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci. 2012; 8: 749-755.
99. Siddiqui AA, Kowalski TE, Kedika R, et al. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study. Gastrointest Endosc. 2013; 77: 669-670.
100. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011; 333: 425.
101. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 363: 1801-1811.
102. Yao JC, Shah MH, Ito T, et al. A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann Oncol. 2010; 21 (suppl 8): viii4. Abstract LBA9.
103. Mayr M, Schmid RM,. Pancreatic cancer and depression: myth and truth. BMC Cancer. 2010; 10: 569.
104. Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 77: 1420-1425.
105. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. 7th ed. New York NY: Springer; 2010.
106. Tamm EP, Balachandran A, Bhosale PR, et al. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am. 2012; 50: 407-428.
107. Vauthey JN, Dixon E,. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol. 2009; 16: 1725-1726.
108. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004; 8: 935-949.
109. Qiu H, Wild AT, Wang H, et al. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol. 2012; 104: 167-172.
110. House MG, Yeo CJ, Cameron JL, et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg. 2004; 8: 280-288.
111. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000; 4: 567-579.
112. Willett CG, Lewandrowski KB, Warshaw AL, Efird J, Corris PA,. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993; 217: 144-148.
113. Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008; 15: 2081-2088.
114. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502.
115. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Comp Cancer Netw. 2012; 10: 703-713.
116. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single institution experience. J Gastrointest Surg. 2006; 10: 1199-1211.
117. Hsu CC, Wolfgang CL, Laheru DA, et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg. 2012; 16: 753-761.
118. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206: 833-846.
119. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J,. Serum CA19-9 determination in the management of pancreatic cancer. Hepatogastroenterology. 1996; 43: 710-713.
120. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J,. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7: e1000267.
121. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C,. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011; 15: 2059-2069.
122. White RR, Paulson EK, Freed KS, et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg. 2001; 5: 626-633.
123. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495.
124. Heinrich S, Pestalozzi BC, Schafer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 2526-2531.
125. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007; 14: 2088-2096.
126. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009; 20: 1387-1396.
127. Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011; 29: 3037-3043.
128. De Jesus-Acosta A, Oliver GR, Blackford A, et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012; 69: 415-424.
129. Chatterjee D, Katz MH, Rashid A, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012; 36: 409-417.
130. Chatterjee D, Rashid A, Wang H, et al. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012; 36: 552-559.
131. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006; 10: 1199-1210.
132. Nathan H, Wolfgang CL, Edil BH, et al. Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol. 2009; 99: 87-92.
133. Karachristos A, Scarmeas N, Hoffman JP,. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005; 9: 1286-1292.
134. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C,. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000; 135: 409-414.
135. Conlon KC, Brennan MF,. Laparoscopy for staging abdominal malignancies. Adv Surg. 2000; 34: 331-350.
136. Gagandeep S, Artinyan A, Jabbour N, et al. Extended pancreatectomy with resection of the celiac axis: the modified Appleby operation. Am J Surg. 2006; 192: 330-335.
137. Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012; 16: 920-926.
138. Kamath AS, Sarr MG, Nagorney DM, et al. Gastrointestinal stromal tumour of the duodenum: single institution experience. HPB (Oxford). 2012; 14: 772-776.
139. Kendrick ML, Sclabas GM,. Major venous resection during total laparoscopic pancreaticoduodenectomy. HPB (Oxford). 2011; 13: 454-458.
140. Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL., Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg. 2012; 255: 1048-1059.
141. Kendrick ML, Cusati D,. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. Arch Surg. 2010; 145: 19-23.
142. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002; 346: 1128-1137.
143. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008; 26: 3503-3510.
144. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-277.
145. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304: 1073-1081.
146. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987; 59: 2006-2010.
147. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230: 776-782.
148. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200-1210.
149. Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704 - a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012; 82: 809-816.
150. Shah AP, Strauss JB, Abrams RA,. Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer. Am J Clin Oncol. 2010; 33: 101-106.
151. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol. 2008; 26: 3511-3516.
152. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010; 17: 981-990.
153. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011; 18: 1319-1326.
154. Picozzi VJ, Abrams RA, Decker PA, et al. American College of Surgeons Oncology Group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011; 22: 348-354.
155. Picozzi VJ, Kozarek RA, Traverso LW,. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003; 185: 476-480.
156. Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012; 30: 4077-4083.
157. Ma WW, Herman JM, Jimeno A, et al. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol. 2010; 3: 373-379.
158. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011; 253: 328-335.
159. Weden S, Klemp M, Gladhaug IP, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011; 128: 1120-1128.
160. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008; 6: 955-964.
161. Minn AY, Koong AC, Chang DT,. Stereotactic body radiation therapy for gastrointestinal malignancies. Front Radiat Ther Oncol. 2011; 43: 412-427.
162. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
163. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011; 29: 4105-4112.
164. Sudo K, Yamaguchi T, Ishihara T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011; 80: 119-125.
165. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010; 28: 1645-1651.
166. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010; 28: 3605-3610.
167. Sawaki A, Hoki N, Ito S, et al. Clinical impact of radiotherapy for locally advanced pancreatic cancer. J Gastroenterol. 2009; 44: 1209-1214.
168. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol. 2009; 27: 4096-4102.
169. Moureau-Zabotto L, Phélip JM, Afchain P, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol. 2008; 26: 1080-1085.
170. Duffy A, Kortmansky J, Schwartz GK, et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol. 2008; 19: 86-91.
171. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25: 326-331.
172. Small W Jr, Mulcahy MF, Rademaker A, et al. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011; 80: 476-482.
173. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26: 942-947.
174. Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 1325-1330.
175. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012; 16: 68-78.
176. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110: 47-55.
177. Mishra G, Butler J, Ho C, et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol. 2005; 28: 345-350.
178. Ko AH, Quivey JM, Venook AP, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 809-816.
179. Wahl RL, Herman JM, Ford E,. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011; 21: 88-100.
180. Spalding AC, Jee KW, Vineberg K, et al. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys. 2007; 34: 521-529.
181. Yovino S, Maidment BW 3rd, Herman JM, et al. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys. 2012; 83: 916-920.
182. Rich TA, Winter K, Safran H, et al. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Onco Targets Ther. 2012; 5: 161-170.
183. Dawson LA, Eccles C, Bissonnette JP, Brock KK,. Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys. 2005; 62: 1247-1252.
184. Goldstein SD, Ford EC, Duhon M, McNutt T, Wong J, Herman JM,. Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2010; 76: 597-602.
185. Khashab MA, Kim KJ, Tryggestad EJ, et al. Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointest Endosc. 2012; 76: 962-971.
186. Poulsen PR, Cho B, Keall PJ,. A method to estimate mean position, motion magnitude, motion correlation, and trajectory of a tumor from cone-beam CT projections for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 72: 1587-1596.
187. Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012; 84: 1166-1171.
188. Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC,. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010; 78: 1420-1426.
189. Fung MC, Takayama S, Ishiguro H, Sakata T, Adachi S, Morizane T,. Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002) [in Japanese]. Gan To Kagaku Ryoho. 2003; 30: 1101-1111.
190. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
191. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21: 3402-3408.
192. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27: 3778-3785.
193. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C,. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008; 8: 82.
194. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P,. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007; 25: 2607-2615.
195. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27: 5513-5518.
196. Louvet C, Labianca R, Hammel P, et al. GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 3509-3516.
197. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-3952.
198. Cui Y, Brosnan JA, Blackford AL, et al. Genetically defined subsets of human pancreatic cancer demonstrate unique in vitro chemosensitivity. Clin Cancer Res. 2012; 18: 6519-6530.
199. Von Hoff D, Ervin TJ, Arena FP, et al. Randomized Phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol. 2013; 30 (suppl 4): abstract LBA148.
200. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
201. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28: 3617-3622.
202. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA,. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008; 113: 2046-2052.
203. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47: 1676-1681.
204. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007; 25: 4787-4792.
205. Arnaoutakis GJ, Rangachari D, Laheru DA, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011; 15: 1611-1617.
206. Yap JL, Worlikar S, MacKerell AD Jr, Shapiro P, Fletcher S,. Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics. ChemMedChem. 2011; 6: 38-48.
207. Collisson EA, Trejo CL, Silva JM, et al. A central role for RAF - >MEK - >ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012; 2: 685-693.
208. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008; 68: 918-926.
209. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J,. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. 2010; 32: 128-131.
210. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331: 1612-1616.
211. Yang S, Kimmelman AC,. A critical role for autophagy in pancreatic cancer. Autophagy. 2011; 7: 912-913.
212. Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25: 717-729.
213. Lim JP, Gleeson PA,. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol Cell Biol. 2011; 89: 836-843.
214. Wise DR, Thompson CB,. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35: 427-433.
215. Kaelin WG Jr, Thompson CB,. Q&A: Cancer: clues from cell metabolism. Nature. 2010; 465: 562-564.
216. Le A, Rajeshkumar NV, Maitra A, Dang CV,. Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res. 2012; 18: 4285-4290.
217. Yan BM, Myers RP,. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol. 2007; 102: 430-438.
218. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA. 2004; 291: 1092-1099.
219. Erdek MA, Halpert DE, González Fernández M, Cohen SP,. Assessment of celiac plexus block and neurolysis outcomes and technique in the management of refractory visceral cancer pain. Pain Med. 2010; 11: 92-100.
220. McGreevy K, Hurley RW, Erdek MA, Aner MM, Li S, Cohen SP,. The effectiveness of repeat celiac plexus neurolysis for pancreatic cancer: a pilot study. Pain Pract. 2013; 13: 89-95.
221. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012; 15: 436-464.
222. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002; 20: 4040-4049.
223. Boyd AD, Brown D, Henrickson C, et al. Screening for depression, sleep-related disturbances, and anxiety in patients with adenocarcinoma of the pancreas: a preliminary study. ScientificWorldJournal. 2012; 2012: 650707.
224. Boyd CA, Benarroch-Gampel J, Sheffield KM, Han Y, Kuo YF, Riall TS,. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Surgery. 2012; 152: 403-413.
225. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; seer.cancer.gov/csr/1975- 2008/. Based on November 2010 SEER data submission, posted to the SEER Web site, 2011.
226. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999; 91: 1310-1316.
227. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000; 119: 1447-1453.
228. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME,. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010; 105: 1258-1264.
229. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987; 316: 1511-1514.
230. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA,. Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet. 2004; 41: 421-424.
231. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010; 42: 224-228.
232. Kalser MH, Ellenberg SS,. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120: 899-903.
233. Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006; 140: 764-772.
234. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299: 1019-1026.
235. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004; 22: 3776-3783.
236. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-3952.
237. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006; 24: 4441-4447.
238. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005; 16: 1639-1645.
239. Kulke MH, Tempero MA, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009; 27: 5506-5512.